Molecular Templates to Present at the Jefferies Global Healthcare Conference
Get Alerts MTEM Hot Sheet
Join SI Premium – FREE
AUSTIN, Texas, May 31, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced that its management will provide a corporate overview at the Jefferies Global Healthcare Conference, taking place June 5-8 at the Grand Hyatt New York hotel in New York City.
| Presentation Details | |
| Date: Time: Webcast: | Thursday, June 78:30am Eastern Timehttp://wsw.com/webcast/jeff113/mtem/ |
About Molecular Templates Molecular Templates is a clinical-stage oncology company focused on the discovery and development of differentiated, targeted, biologic therapeutics for cancer. We believe our proprietary biologic drug platform technology, referred to as engineered toxin bodies, or ETBs, provides a differentiated mechanism of action that may address some of the limitations associated with currently available cancer therapeutics. ETBs utilize a genetically engineered form of Shiga-like Toxin A subunit, or SLTA, a ribosome inactivating bacterial protein, that can be targeted to specifically destroy cancer cells. Additional information about Molecular Templates can be obtained at http://www.mtem.com.
Investor Contact: Andrew McDonald, Ph.D. [email protected] 646-597-6987
Adam CutlerChief Financial Officer [email protected] 862-204-4006
Source: Molecular Templates, Inc.
Source: Molecular Templates, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Imperium AI CEO, Founder and Filmmaker Shazir Mucklai Explores $1 Million Offer to Reunite Jennifer Lopez and Ben Affleck for Romantic-Comedy Video Project
- Docebo Inc. Announces Substantial Issuer Bid Price Increase and Extension
- The Metals Royalty Company Announces Fully Allocated US$165 Million Financing to Fund Acquisition of Additional 1.0% Mesabi Royalty
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share